Industry News

Pharmaceutical major Cipla Limited has announced the signing of definitive agreements to acquire 100% equity stake in Inzpera Healthsciences Limited, a company engaged in developing and marketing differentiated paediatric and wellness products. The announcement was made through a corporate filing with the Bombay Stock Exchange

Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received tentative approval from the United States Food and Drug Administration (USFDA) for Budesonide delayed-release capsules, 4 mg (USRLD: Tarpeyo Capsules, 4 mg).

Pfizer Inc. announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery. The lawsuit includes claims for breach of contract, breach of fiduciary duty, and tortious interference in contract arising from Metseras alleged breach of its obligations under the merger agreement between Pfizer and Metsera.

Teva Pharmaceuticals USA, Inc., and affiliated companies have agreed to pay USD 35 million to resolve a class action lawsuit alleging that the drugmaker delayed generic competition for its asthma inhaler, QVAR

Merck known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 LITESPARK-022 trial in patients with clear cell renal cell carcinoma (RCC) following nephrectomy. In this study, KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with WELIREG

Global pharmaceutical leader, Lupin Limited (Lupin), commemorated the inauguration of its new corporate offices at 100 Somerset Corporate Blvd in Bridgewater, New Jersey. The new location expands Lupin’s presence in the state, which already includes manufacturing and research facilities in Somerset.

Dr Reddys Laboratories Ltd, one of Indias leading pharmaceutical companies, plans to launch a lower-cost generic version of Novo Nordisks blockbuster weight-loss drug Wegovy across 87 countries next year, according to the company’s Chief Executive Officer, Erez Israeli.

GSK plc announced the US Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory (IMID) agent.

Avidity is committed to delivering a new class of pioneering RNA therapeutics called Antibody Oligonucleotide Conjugates for serious, genetic neuromuscular diseases. The proposed acquisition will bring Aviditys late-stage neuroscience programs into Novartis and provide Novartis access to a differentiated RNA-targeting delivery platform.